

# ASX ANNOUNCEMENT

## SERVICES AGREEMENT WITH CODE4 CANNABIS

**23 APRIL 2024**

**Melbourne, Australia** – The Board of Vitura Health Limited (ASX: VIT) (**Company** or **Vitura**), a leading digital health platform business, advises that it has received confirmation from Code4 Cannabis Pty. Ltd. (**C4C**) of its intention to terminate its Services Agreement with Vitura’s wholly-owned subsidiary Canview Pty. Ltd. (**Canview**), to be effective from 29 April 2024.

On 27 December 2023, the Company announced that C4C had notified that C4C does not intend to extend the Services Agreement pursuant to which Vitura exclusively licenses software used as part of the Canview platform (**Software**) beyond its expiry date of 10 August 2024, and that Vitura had exercised its right under the Services Agreement to enact a 15-month transitional period until 10 November 2025.

Vitura and Canview do not agree that C4C is entitled to terminate the Services Agreement and has advised C4C accordingly.

Vitura and Canview have now issued proceedings to restrain C4C from withholding services. The proceedings will be heard in the Supreme Court of Queensland in Brisbane on Friday, 26 April 2024.

In the event that C4C ceases to provide services under the Services Contract from 29 April 2024, as threatened, and given the limited time to implement alternative arrangements, it is likely that there will be a material disruption to Vitura’s operations, which may not be fully addressed by the implementation of its business continuity plans.

Vitura will keep the market updated in accordance with its continuous disclosure obligations.

**\*\* ENDS \*\***



## About Vitura Health Limited (ASX: VIT)

[www.vitura.com.au](http://www.vitura.com.au)

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- [www.burleighheadscannabis.com](http://www.burleighheadscannabis.com)  
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 440+ therapeutic product and device SKUs within Australia from approximately 42 international and domestic brands.
- [www.canview.com.au](http://www.canview.com.au)  
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,400 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- [www.doctorsondemand.com.au](http://www.doctorsondemand.com.au)  
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.



- [www.cortexa.com.au](http://www.cortexa.com.au)

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- [www.cdaclinics.com.au](http://www.cdaclinics.com.au)

The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- [www.cannadoc.com.au](http://www.cannadoc.com.au)

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

### **Authorised by**

Robert Iervasi, Chair and Non-Executive Director

### **Contact**

#### **Vitura Health Limited**

Robert Iervasi  
Chair  
1300 799 491  
[info@vitura.com.au](mailto:info@vitura.com.au)

#### **Media enquiries**

Tim Fogarty  
The Civic Partnership  
+61 400 179 075  
[tim.fogarty@civicpartners.com.au](mailto:tim.fogarty@civicpartners.com.au)

### **Forward-looking statements**

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.